ChiCTR2100048270 版本V1.2 版本创建时间2022/01/29 17:05:25 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2100048270 

最近更新日期:

Date of Last Refreshed on:

2022-01-29 16:57:23 

注册时间:

Date of Registration:

2021-07-05 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

请与我们联系上传伦理批件。 中国癌痛患者止痛知识的研究

Public title:

Research on knowledge of pain relief in cancer pain patients in China

注册题目简写:

English Acronym:

研究课题的正式科学名称:

探索中国癌痛患者止痛知识与止痛效果相关性的观察性研究

Scientific title:

Observational study to explore the correlation between analgesic knowledge and analgesic effect in cancer pain patients in China

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

任夏洋 

研究负责人:

任夏洋 

Applicant:

Ren Xiayang 

Study leader:

Ren Xiayang 

申请注册联系人电话:

Applicant telephone:

+86 15010377247

研究负责人电话:

Study leader's telephone:

+86 15010377247

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

erxia100@163.com

研究负责人电子邮件:

Study leader's E-mail:

erxia100@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

北京市朝阳区潘家园南里18号

研究负责人通讯地址:

北京市朝阳区潘家园南里18号

Applicant address:

18 Panjiayuan Lane South, Chaoyang District, Beijing

Study leader's address:

18 Panjiayuan Lane South, Chaoyang District, Beijing

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

中国医学科学院肿瘤医院

Applicant's institution:

Cancer Hospital of Chinese Academy of Medical Sciences

研究负责人所在单位:

中国医学科学院肿瘤医院

Affiliation of the Leader:

Cancer Hospital of Chinese Academy of Medical Sciences

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2021031709464502

伦理委员会批件附件:

Approved file of Ethical Committee:

批准本研究的伦理委员会名称:

中国医学科学院肿瘤医院伦理委员会

Name of the ethic committee:

Ethics Committee of Cancer Hospital of Chinese Academy of Medical Sciences

伦理委员会批准日期:

Date of approved by ethic committee:

1990-01-01 00:00:00

伦理委员会联系人:

李宁

Contact Name of the ethic committee:

Li Ning

伦理委员会联系地址:

北京市朝阳区潘家园南里18号

Contact Address of the ethic committee:

18 Panjiayuan Lane South, Chaoyang District, Beijing

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

中国医学科学院肿瘤医院

Primary sponsor:

Cancer Hospital of Chinese Academy of Medical Sciences

研究实施负责(组长)单位地址:

北京市朝阳区潘家园南里18号

Primary sponsor's address:

18 Panjiayuan Lane South, Chaoyang District, Beijing

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

中国医学科学院肿瘤医院

具体地址:

朝阳区潘家园南里18号

Institution
hospital:

Cancer Hospital of Chinese Academy of Medical Sciences

Address:

18 Panjiayuan Lane South, Chaoyang District

经费或物资来源:

自筹

Source(s) of funding:

self-funded

Target disease:

Cancer pain

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

横断面 

Study design:

Cross-sectional 

研究目的:

1. 调查我院门诊和住院癌痛患者止痛知识的掌握情况; 2. 分析患者止痛知识和其止痛效果的相关性。  

Objectives of Study:

1. Investigate the knowledge of pain relief for outpatient and inpatient cancer pain patients in our hospital; 2. To analyze the correlation between patients' analgesic knowledge and their analgesic effect.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.恶性肿瘤的诊断;
2.癌症疼痛诊断;
3.根据WHO三阶梯原则服/使用止痛药物;
4.服/使用止痛药物≥3天;
5.意识清楚,能准确表达自己的想法;
6.电话随访的患者需言语顺畅,清晰交流,问诊患者若言语表达障碍,需书面交流顺畅;
7.接受药师随访和问诊。

Inclusion criteria

1. Diagnosis of malignant tumor;
2. Cancer pain diagnosis;
3. Take/use painkillers according to the WHO three-step principle;
4. Take/use pain medication for >=3 days;
5. Clear awareness and able to express their thoughts accurately;
6. Patients who are followed up by telephone need to communicate smoothly and clearly. If the patients who are interviewed have difficulty in verbal expression, they need to communicate smoothly in writing;
7. Receive follow-up visits and consultations from pharmacists.

排除标准:

加用自行购买或外院开具的止痛药。

Exclusion criteria:

Add painkillers purchased by yourself or prescribed by an outside hospital.

研究实施时间:

Study execute time:

From 2021-08-01 00:00:00 To 2022-05-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2021-08-01 00:00:00 To 2022-05-01 00:00:00  

干预措施:

Interventions:

组别:

连续入组

样本量:

70

Group:

case series

Sample size:

干预措施:

干预措施代码:

Intervention:

none

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

China 

Province:

Beijing 

City:

 

单位(医院):

中国医学科学院肿瘤医院 

单位级别:

三级甲等 

Institution
hospital:

Cancer Hospital of Chinese Academy of Medical Sciences

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

止痛知识

指标类型:

主要指标

Outcome:

Knowledge of cancer pain

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

none

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

本试验设计不进行随机

Randomization Procedure (please state who generates the random number sequence and by what method):

The design was not randomized

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

以发表论文的方式公开

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

By paper

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

通过随访和问诊的形式采集数据

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Data were collected through follow-up and consultation

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2021-07-05 08:23:28